Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | CASP1 | P29466 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | NPEPPS | P55786 | 1/20 | 0.48 |
| ▸ | GPR88 | Q9GZN0 | 10/20 | 0.45 |
| ▸ | ITK | Q08881 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | NOS2 | P35228 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL902977 | 1.00 | KDM4E (0.51) | KDM4ECASP1HSD17B10NPEPPSGPR88 | |
| SCHEMBL14059266 | 1.00 | KDM4E (0.51) | KDM4ECASP1HSD17B10NPEPPSGPR88 | |
| SCHEMBL901459 | 1.00 | KDM4E (0.51) | KDM4ECASP1HSD17B10NPEPPSGPR88 | |
| SCHEMBL901429 | 1.00 | KDM4E (0.51) | KDM4ECASP1HSD17B10NPEPPSGPR88 | |
| SCHEMBL7214698 | 0.84 | MAPT (0.51) | KDM4ECASP1HSD17B10NPEPPSMAPT | |
| SCHEMBL7214703 | 0.84 | MAPT (0.51) | KDM4ECASP1HSD17B10NPEPPSMAPT | |
| SCHEMBL7214700 | 0.84 | MAPT (0.51) | KDM4ECASP1HSD17B10NPEPPSMAPT | |
| SCHEMBL18706738 | 0.84 | ITK (0.51) | KDM4ECASP1HSD17B10GPR88ITK | |
| SCHEMBL15797898 | 0.82 | NOS3 (0.43) | KDM4ECASP1HSD17B10MAPTPKM | |
| SCHEMBL15805100 | 0.82 | NOS3 (0.43) | KDM4ECASP1HSD17B10MAPTPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230067237-A1 | CAFFEINE INHIBITORS OF MTHFD2 AND USES THEREOF | RAZE THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
| US-11370792-B2 | Caffeine inhibitors of MTHFD2 and uses thereof | RAZE THERAPEUTICS, INC. (US) | 2022-06-28 | — | — | US | disclosed |
| EP-2621276-B1 | 2-ALKOXY PYRIMIDINE PDE10 INHIBITORS | MERCK SHARP & DOHME (US) | 2017-12-27 | — | — | EP | disclosed |
| WO-2017106352-A1 | CAFFEINE INHIBITORS OF MTHFD2 AND USES THEREOF | RAZE THERAPEUTICS, INC. (US) | 2017-06-22 | — | — | WO | disclosed |
| US-20140343053-A1 | TRIAZOLOPYRIDINONE PDE10 INHIBITORS | MERCK SHARPE & DOHME CORP. (US) | 2014-11-20 | — | — | US | disclosed |
| US-20140343053-A1 | TRIAZOLOPYRIDINONE PDE10 INHIBITORS | MERCK SHARPE & DOHME CORP. (US) | 2014-11-20 | — | — | US | disclosed |
| US-8785467-B2 | Alkoxy pyrimidine PDE10 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-07-22 | — | — | US | disclosed |
| US-8785467-B2 | Alkoxy pyrimidine PDE10 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-07-22 | — | — | US | disclosed |
| US-20130158056-A1 | ALKOXY PYRIMIDINE PDE10 INHIBITORS | MERCK SHARP & DOHME LLC | 2013-06-20 | — | — | US | disclosed |
| US-20130158056-A1 | ALKOXY PYRIMIDINE PDE10 INHIBITORS | MERCK SHARP & DOHME LLC | 2013-06-20 | — | — | US | disclosed |
| WO-2013074390-A1 | TRIAZOLOPYRIDINONE PDE10 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2013-05-23 | — | — | WO | disclosed |
| WO-2012044561-A2 | 2-ALKOXY PYRIMIDINE PDE10 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2012-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158056-A1 | ALKOXY PYRIMIDINE PDE10 INHIBITORS | PDE10A, PDE11A, PDE12 | KDM4E 1736/4885CASP1 3212/4885HSD17B10 173/4885 |
| US-20140343053-A1 | TRIAZOLOPYRIDINONE PDE10 INHIBITORS | PDE12, PDE10A, PDE5A | KDM4E 1143/4885CASP1 3697/4885HSD17B10 80/4885 |
| US-11370792-B2 | Caffeine inhibitors of MTHFD2 and uses thereof | MTHFD2, MTHFD1, NUDT15 | KDM4E 1934/4885CASP1 3060/4885HSD17B10 129/4885 |
| US-20230067237-A1 | CAFFEINE INHIBITORS OF MTHFD2 AND USES THEREOF | MTHFD2, MTHFD1, NUDT15 | KDM4E 1934/4885CASP1 3060/4885HSD17B10 129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.